Cardiff Oncology and Nerviano Medical Sciences are seeking FDA regulatory review for Phase 3 trials and managing a licensing dispute over onvansertib.
2 reports, 2 independent
Updated Oct 1
Gone quiet
- Reports
- 2
- Developments
- 2
- Repetition
- 0%
New informationRepeats or wire copies
AI-generated analysis. Brind wrote this summary from the reports listed below. It can be wrong. Each section says how much you can rely on it, and the sources are linked so you can check.
What happened
Cardiff Oncology and Nerviano Medical Sciences are seeking FDA regulatory review for Phase 3 trials and managing a licensing dispute over onvansertib.
Who's involved
What this event is mainly aboutFDANerviano Medical Sciences
How it developed
Newest first. Tap a step to see who reported it.FDA granted Orphan Drug Designation for onvansertib, and data was presented at ASH.1 source
Seeking FDA approval for Phase 3 trials while navigating a licensing dispute.1 source
Keep exploring
The entities involved
Related events
- A company is conducting clinical trials and seeking drug approval for the U.S. market under the FDA.
- An AI-designed drug is currently in trials, prompting a focus on global legal and ethical standards.
- FDA removed the clinical hold on Arbutus Biopharma Corporation's IND application, allowing potential clinical development.
- The FDA reversed its decision regarding a gene therapy application from uniQure N.V.